Duffy et al. (2016) evaluated the impact of the antisense oligonucleotide ISIS 183750 targeting eIF4E in a clinical trial including mainly patients with CRC (NCT01675128) [233]. This evidence concerns the gene EIF4E and colorectal carcinoma.